BOAN BIOTECH (06955) Rises Nearly 7% in Early Trading as Aflibercept Ophthalmic Injection Solution Gains NMPA Approval

Stock News11-27

BOAN BIOTECH (06955) surged nearly 7% in early trading, with gains moderating to 4.3% at the time of writing, reaching HK$10.91 and a turnover of HK$21.45 million.

On November 26, BOAN BIOTECH announced that its self-developed Boanji® (Aflibercept Ophthalmic Injection Solution) has officially received marketing approval from China's National Medical Products Administration (NMPA). The drug is indicated for treating neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults.

The company will collaborate with China's leading ophthalmic pharmaceutical platform, Ocumension Therapeutics, to commercialize the product in mainland China. Boanji® is a biosimilar to EYLEA® (Aflibercept), with its active ingredient being a humanized fusion protein. Compared to anti-VEGF monoclonal antibodies, it binds more broadly to vascular endothelial growth factors (VEGF-A, VEGF-B) and placental growth factor (PlGF).

As a first-line treatment for nAMD, DME, and other retinal diseases, Aflibercept offers prolonged VEGF suppression in the eye, effectively improving vision with long-term efficacy and favorable overall safety and tolerability.

Beyond China, BOAN BIOTECH is actively advancing Boanji®'s global expansion. The company has previously granted Sinovac Biotech's wholly-owned subsidiary, Shenzhen Sinovac Biopharmaceutical, exclusive sales rights for the product in regions excluding mainland China, the EU, the UK, the U.S., and Japan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113894742?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113894742","market":"us","top_or_hot":-1,"title":"BOAN BIOTECH (06955) Rises Nearly 7% in Early Trading as Aflibercept Ophthalmic Injection Solution Gains NMPA Approval","media":"Stock News","content":"<p>BOAN BIOTECH (06955) surged nearly 7% in early trading, with gains moderating to 4.3% at the time of writing, reaching HK$10.91 and a turnover of HK$21.45 million.</p>\n<p>On November 26, BOAN BIOTECH announced that its self-developed Boanji® (Aflibercept Ophthalmic Injection Solution) has officially received marketing approval from China's National Medical Products Administration (NMPA). The drug is indicated for treating neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults.</p>\n<p>The company will collaborate with China's leading ophthalmic pharmaceutical platform, Ocumension Therapeutics, to commercialize the product in mainland China. Boanji® is a biosimilar to EYLEA® (Aflibercept), with its active ingredient being a humanized fusion protein. Compared to anti-VEGF monoclonal antibodies, it binds more broadly to vascular endothelial growth factors (VEGF-A, VEGF-B) and placental growth factor (PlGF).</p>\n<p>As a first-line treatment for nAMD, DME, and other retinal diseases, Aflibercept offers prolonged VEGF suppression in the eye, effectively improving vision with long-term efficacy and favorable overall safety and tolerability.</p>\n<p>Beyond China, BOAN BIOTECH is actively advancing Boanji®'s global expansion. The company has previously granted Sinovac Biotech's wholly-owned subsidiary, Shenzhen Sinovac Biopharmaceutical, exclusive sales rights for the product in regions excluding mainland China, the EU, the UK, the U.S., and Japan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOAN BIOTECH (06955) Rises Nearly 7% in Early Trading as Aflibercept Ophthalmic Injection Solution Gains NMPA Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOAN BIOTECH (06955) Rises Nearly 7% in Early Trading as Aflibercept Ophthalmic Injection Solution Gains NMPA Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BOAN BIOTECH (06955) surged nearly 7% in early trading, with gains moderating to 4.3% at the time of writing, reaching HK$10.91 and a turnover of HK$21.45 million.</p>\n<p>On November 26, BOAN BIOTECH announced that its self-developed Boanji® (Aflibercept Ophthalmic Injection Solution) has officially received marketing approval from China's National Medical Products Administration (NMPA). The drug is indicated for treating neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults.</p>\n<p>The company will collaborate with China's leading ophthalmic pharmaceutical platform, Ocumension Therapeutics, to commercialize the product in mainland China. Boanji® is a biosimilar to EYLEA® (Aflibercept), with its active ingredient being a humanized fusion protein. Compared to anti-VEGF monoclonal antibodies, it binds more broadly to vascular endothelial growth factors (VEGF-A, VEGF-B) and placental growth factor (PlGF).</p>\n<p>As a first-line treatment for nAMD, DME, and other retinal diseases, Aflibercept offers prolonged VEGF suppression in the eye, effectively improving vision with long-term efficacy and favorable overall safety and tolerability.</p>\n<p>Beyond China, BOAN BIOTECH is actively advancing Boanji®'s global expansion. The company has previously granted Sinovac Biotech's wholly-owned subsidiary, Shenzhen Sinovac Biopharmaceutical, exclusive sales rights for the product in regions excluding mainland China, the EU, the UK, the U.S., and Japan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"","article_id":"1113894742","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113894742","pubTimestamp":1764207502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BOAN BIOTECH (06955) surged nearly 7% in early trading, with gains moderating to 4.3% at the time of writing, reaching HK$10.91 and a turnover of HK$21.45 million. On November 26, BOAN BIOTECH...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06955":"博安生物","BK1161":"生物科技"},"translate_title":"阿柏西普眼用注射液获NMPA批准博安生物(06955)早盘涨近7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1},"content_text":"BOAN BIOTECH (06955) surged nearly 7% in early trading, with gains moderating to 4.3% at the time of writing, reaching HK$10.91 and a turnover of HK$21.45 million.\nOn November 26, BOAN BIOTECH announced that its self-developed Boanji® (Aflibercept Ophthalmic Injection Solution) has officially received marketing approval from China's National Medical Products Administration (NMPA). The drug is indicated for treating neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults.\nThe company will collaborate with China's leading ophthalmic pharmaceutical platform, Ocumension Therapeutics, to commercialize the product in mainland China. Boanji® is a biosimilar to EYLEA® (Aflibercept), with its active ingredient being a humanized fusion protein. Compared to anti-VEGF monoclonal antibodies, it binds more broadly to vascular endothelial growth factors (VEGF-A, VEGF-B) and placental growth factor (PlGF).\nAs a first-line treatment for nAMD, DME, and other retinal diseases, Aflibercept offers prolonged VEGF suppression in the eye, effectively improving vision with long-term efficacy and favorable overall safety and tolerability.\nBeyond China, BOAN BIOTECH is actively advancing Boanji®'s global expansion. The company has previously granted Sinovac Biotech's wholly-owned subsidiary, Shenzhen Sinovac Biopharmaceutical, exclusive sales rights for the product in regions excluding mainland China, the EU, the UK, the U.S., and Japan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113894742","isCrawlerRequest":true}